Glaukos (NYSE:GKOS) Stock Rating Upgraded by Mizuho

Mizuho upgraded shares of Glaukos (NYSE:GKOS) from a neutral rating to an outperform rating in a research report report published on Wednesday, MarketBeat Ratings reports. Mizuho currently has $200.00 target price on the medical instruments supplier’s stock, up from their previous target price of $140.00.

A number of other research analysts have also recently weighed in on GKOS. JPMorgan Chase & Co. lifted their price objective on shares of Glaukos from $130.00 to $145.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Truist Financial boosted their price target on shares of Glaukos from $152.00 to $185.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Piper Sandler reiterated an “overweight” rating and issued a $180.00 price objective (up from $140.00) on shares of Glaukos in a research note on Monday, January 27th. UBS Group began coverage on Glaukos in a research note on Friday, December 6th. They set a “buy” rating and a $182.00 target price for the company. Finally, Morgan Stanley lowered Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price target on the stock. in a research report on Monday, December 2nd. One analyst has rated the stock with a sell rating, one has given a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Glaukos has a consensus rating of “Moderate Buy” and a consensus target price of $163.25.

Glaukos Trading Down 19.9 %

GKOS opened at $126.03 on Wednesday. Glaukos has a 52 week low of $83.90 and a 52 week high of $163.71. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The business has a fifty day simple moving average of $152.75 and a 200-day simple moving average of $139.25. The firm has a market cap of $6.95 billion, a P/E ratio of -41.73 and a beta of 1.04.

Glaukos (NYSE:GKOS) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). The firm had revenue of $105.50 million for the quarter, compared to analysts’ expectations of $100.72 million. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. On average, equities analysts expect that Glaukos will post -1.89 earnings per share for the current year.

Insider Activity

In related news, insider Tomas Navratil sold 3,416 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the transaction, the insider now directly owns 72,437 shares of the company’s stock, valued at $10,658,380.18. This trade represents a 4.50 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Gilbert H. Kliman sold 10,000 shares of the business’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $150.28, for a total transaction of $1,502,800.00. Following the completion of the sale, the director now directly owns 32,336 shares of the company’s stock, valued at approximately $4,859,454.08. This trade represents a 23.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,744 shares of company stock worth $2,792,151. 6.40% of the stock is currently owned by insiders.

Institutional Trading of Glaukos

Large investors have recently made changes to their positions in the company. Values First Advisors Inc. purchased a new stake in Glaukos in the third quarter valued at approximately $25,000. IFP Advisors Inc acquired a new position in shares of Glaukos in the 4th quarter valued at $43,000. Asset Planning Inc acquired a new position in shares of Glaukos in the 4th quarter valued at $90,000. CoreCap Advisors LLC raised its position in Glaukos by 36.4% in the 4th quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier’s stock valued at $112,000 after purchasing an additional 200 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd boosted its stake in Glaukos by 2,263.2% during the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock worth $117,000 after purchasing an additional 860 shares during the period. 99.04% of the stock is owned by institutional investors and hedge funds.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.